Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Neogene Therapeutics, founded in 2018 and headquartered in Amsterdam, Netherlands, is a pre-clinical stage biotechnology company focused on developing innovative cancer treatments. The company specializes in T-cell therapies targeting neo-antigens, which are mutated proteins present in cancer cells due to DNA mutations. This approach aims to provide more personalized and effective cancer treatments for patients.
Since its inception, Neogene Therapeutics has made significant strides in the biotechnology sector, raising a total of $125 million in funding. This substantial investment demonstrates the confidence of investors in the company's potential and its innovative approach to cancer therapy. In a notable development, AstraZeneca acquired Neogene Therapeutics in November 2022 for a reported sum between $200 million and $320 million.
Given the recent acquisition by AstraZeneca, the prospects of a Neogene Therapeutics IPO are currently uncertain. As a subsidiary of a larger pharmaceutical company, the likelihood of a separate public offering for Neogene Therapeutics has significantly decreased. However, investors interested in the company's technology and potential may consider exploring investment opportunities in AstraZeneca, which now owns Neogene Therapeutics.
It's important to note that the biotechnology sector is known for its dynamic nature, with frequent mergers, acquisitions, and strategic partnerships. While Neogene Therapeutics' innovative approach to cancer treatment continues to generate interest, any discussions about its stock or public offering remain speculative at this time.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Neogene Therapeutics' IPO prospects remain uncertain, investors eager to explore opportunities in the innovative cancer therapeutics space don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the biotech and healthcare sectors, like Neogene Therapeutics, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from their growth and breakthroughs in cancer treatment before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
